作者
Christopher B Granger, John H Alexander, John JV McMurray, Renato D Lopes, Elaine M Hylek, Michael Hanna, Hussein R Al-Khalidi, Jack Ansell, Dan Atar, Alvaro Avezum, M Cecilia Bahit, Rafael Diaz, J Donald Easton, Justin A Ezekowitz, Greg Flaker, David Garcia, Margarida Geraldes, Bernard J Gersh, Sergey Golitsyn, Shinya Goto, Antonio G Hermosillo, Stefan H Hohnloser, John Horowitz, Puneet Mohan, Petr Jansky, Basil S Lewis, Jose Luis Lopez-Sendon, Prem Pais, Alexander Parkhomenko, Freek WA Verheugt, Jun Zhu, Lars Wallentin
发表日期
2011/9/15
期刊
New England Journal of Medicine
卷号
365
期号
11
页码范围
981-992
出版商
Massachusetts Medical Society
简介
Background
Vitamin K antagonists are highly effective in preventing stroke in patients with atrial fibrillation but have several limitations. Apixaban is a novel oral direct factor Xa inhibitor that has been shown to reduce the risk of stroke in a similar population in comparison with aspirin.
Methods
In this randomized, double-blind trial, we compared apixaban (at a dose of 5 mg twice daily) with warfarin (target international normalized ratio, 2.0 to 3.0) in 18,201 patients with atrial fibrillation and at least one additional risk factor for stroke. The primary outcome was ischemic or hemorrhagic stroke or systemic embolism. The trial was designed to test for noninferiority, with key secondary objectives of testing for superiority with respect to the primary outcome and to the rates of major bleeding and death from any cause.
Results
The median duration of follow-up was 1.8 years. The rate of the primary outcome was 1.27% per …
引用总数
学术搜索中的文章
CB Granger, JH Alexander, JJV McMurray, RD Lopes… - New England Journal of Medicine, 2011
CB Granger, JH Alexander, JJ McMurray, RD Lopes… - Apixaban versus warfarin in patients with atrial …, 2011